Loading…
Biohaven Ltd. is projected to rise to $11.61 by 2027, a +3% move from its current price of $11.29. BHVN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $10.83 | $11.30 | $11.79 | +0.07% |
| May 30 | $10.65 | $11.31 | $12.00 | +0.14% |
| May 31 | $10.52 | $11.31 | $12.17 | +0.21% |
| Jun 1 | $10.40 | $11.32 | $12.32 | +0.28% |
| Jun 2 | $10.31 | $11.33 | $12.45 | +0.35% |
| Jun 3 | $10.22 | $11.34 | $12.57 | +0.42% |
| Jun 4 | $10.15 | $11.34 | $12.69 | +0.49% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.15 | $11.34 | $12.69 | +0.49% |
| Week 2 | $9.73 | $11.40 | $13.35 | +0.97% |
| Week 3 | $9.44 | $11.46 | $13.90 | +1.47% |
| Week 4 | $9.21 | $11.51 | $14.39 | +1.96% |
| Week 5 | $9.01 | $11.57 | $14.85 | +2.45% |
| Week 6 | $8.84 | $11.62 | $15.28 | +2.95% |
| Week 7 | $8.69 | $11.68 | $15.70 | +3.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Biohaven Ltd. (BHVN) is a biopharmaceutical company in the Healthcare sector focused on the discovery, development, and commercialization of treatments across immunology, neuroscience, and oncology worldwide. The company operates within a broad pipeline of BHV programs spanning multiple therapeutic areas and stages of development.
Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
It was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. The pipeline includes BHV-1300 (Phase 2) for Graves’ disease and rheumatoid arthritis, BHV-1400 (Phase 2) for IgA nephropathy, BHV-1600 (Phase 1) for peripartum cardiomyopathy, BHV-8000 (Phase 3) for Parkinson’s disease, Opakalim (Phase 3) for focal epilepsy, BHV-2100 (Phase 2) for pain disorders, BHV-2000 (Phase 2) for obesity, BHV-1510 (Phase 2) for advanced or metastatic epithelial tumors, and BHV-1530 (Phase 2) for urothelial cancer and other tumors.
Its preclinical pipeline includes BHV-1310, BHV-1320, BHV-1450, BHV-1420, BHV-1440, BHV-6500, BHV-1490, BHV-8100, and BHV-1955."
Biohaven Ltd. (BHVN) is currently priced at $11.29 with a market cap of $1.7B and a rank of 2116. The stock trades in a context defined by a 30-day range of $8.55 to $14.91, reflecting near-term volatility within a broader price path.
The 50-day simple moving average is $9.48 and the 200-day simple moving average is $11.85, placing the current price near key moving-average levels. Support sits at $8.39 and resistance at $11.29, framing potential near-term moves around these thresholds.
Looking ahead, the year-by-year forecast shows mixed to bullish momentum, with 2026 at an avg of $11.29 and 2027 at $11.61, then accelerating into a bullish trajectory toward 2050, where the avg is $64.49 and the max is $143.66, supported by a long-run bullish sentiment through the period."
A major floor 34.2% below — a decisive break under it would weaken the trend.
The nearest floor, 25.7% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 21.9% above — clearing it would confirm fresh momentum.
Key BHVN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BHVN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.83 | Buy | $10.07 | Buy |
| MA 10 | $9.28 | Buy | $9.67 | Buy |
| MA 20 | $9.45 | Buy | $9.56 | Buy |
| MA 50 | $9.48 | Buy | $9.76 | Buy |
| MA 100 | $10.45 | Buy | $10.42 | Buy |
| MA 200 | $11.85 | Sell | $12.82 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.74 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 243.25 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.19 | Buy |
| ROC (12) | 14.50 | Buy |
| Bollinger %B (20,2) | 1.21 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.23 | Sell |
| Awesome (5,34) | 0.10 | Buy |
| Ultimate (7,14,28) | 76.08 | Sell |
| Momentum (10) | 2.09 | Buy |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 10.47 | Buy |
| ADX (14) | 13.74 | Neutral |
| ATR (14) | 0.39 | Info |
The 30-day technical picture is bullish, with RSI14 at 70 indicating positive momentum. The stock’s price is above the 50-day moving average of $9.48 and sits just below the 200-day moving average of $11.85.
The current price of $11.29 sits near resistance at $11.29 and above the $8.39 support level, within the 30-day trading range of $8.55 to $14.91.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.09 | $11.29 | $16.63 | 0% | Neutral | |
| $8.72 | $11.61 | $16.62 | +3% | Neutral | |
| $10.65 | $14.83 | $22.34 | +31% | Bullish | |
| $12.98 | $18.77 | $29.43 | +66% | Bullish | |
| $12.86 | $19.25 | $31.21 | +70% | Bullish | |
| $13.23 | $20.45 | $34.13 | +81% | Bullish | |
| $11.65 | $18.55 | $31.77 | +64% | Bullish | |
| $11.73 | $19.22 | $33.69 | +70% | Bullish | |
| $14.85 | $25.00 | $44.77 | +121% | Bullish | |
| $15.61 | $26.98 | $49.29 | +139% | Bullish | |
| $17.61 | $34.51 | $68.41 | +206% | Bullish | |
| $29.02 | $64.49 | $143.66 | +471% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $8.09 | $11.29 | $13.28 | +0.00% |
| June 2026 | $9.58 | $11.38 | $13.95 | +0.83% |
| July 2026 | $9.99 | $12.03 | $15.04 | +5.64% |
| August 2026 | $9.86 | $12.00 | $15.25 | -0.20% |
| September 2026 | $9.76 | $11.98 | $15.42 | -0.15% |
| October 2026 | $10.29 | $12.73 | $16.57 | +6.26% |
| November 2026 | $10.51 | $13.09 | $17.20 | +2.78% |
| December 2026 | $10.00 | $12.54 | $16.63 | -4.22% |
Click any year to see its month-by-month BHVN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BHVN price prediction for 2026 points to an average of $11.29 (low $8.09, high $16.63) — a potential gain of 0% on today's $11.29. A consolidation phase looks the most probable path here.
In 2027, BHVN is projected to trade between $8.72 and $16.62, averaging $11.61 — a potential gain of +3% from today's $11.29. That is up +3% on the projected 2026 average. Price action looks broadly range-bound.
Biohaven Ltd.'s 2028 outlook centres on $14.83, within a $10.65 to $22.34 range. That is up +28% on the projected 2027 average. That marks a +31% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, BHVN could reach as high as $29.43, with a base case around $18.77 and support toward $12.98 — roughly +66% from $11.29. Momentum favours further upside here.
Expect BHVN to range from $12.86 to $31.21 through 2030. The $19.25 average target implies a +70% move from current prices. That is up +3% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The BHVN price prediction for 2031 points to an average of $20.45 (low $13.23, high $34.13) — a potential gain of +81% on today's $11.29. Momentum favours further upside here.
In 2032, BHVN is projected to trade between $11.65 and $31.77, averaging $18.55 — a potential gain of +64% from today's $11.29. That is -9% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Biohaven Ltd.'s 2033 outlook centres on $19.22, within a $11.73 to $33.69 range. That is up +4% on the projected 2032 average. That marks a +70% change versus current levels. Momentum favours further upside here.
By 2034, BHVN could reach as high as $44.77, with a base case around $25.00 and support toward $14.85 — roughly +121% from $11.29. Buyers look set to stay in control over this stretch.
Expect BHVN to range from $15.61 to $49.29 through 2035. The $26.98 average target implies a +139% move from current prices. That is up +8% on the projected 2034 average. Momentum favours further upside here.
The BHVN price prediction for 2040 points to an average of $34.51 (low $17.61, high $68.41) — a potential gain of +206% on today's $11.29. Buyers look set to stay in control over this stretch.
In 2050, BHVN is projected to trade between $29.02 and $143.66, averaging $64.49 — a potential gain of +471% from today's $11.29. That is up +87% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in BHVN today (≈ 88.573959 BHVN) could be worth
$5,712.43
+$4,712.43 (+471%) by 2050 · US Dollar
Based on the average projected BHVN price of $64.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BHVNwould be worth at today's price.
$1,000 invested in BHVN on May 27, 2025 (≈ 65.189048 BHVN) would be worth
$735.98
-$264.02 (-26.4%) today · 0.74× · US Dollar
Based on a BHVN entry price of $15.34 vs. today's $11.29.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.85 | $1,275.71 | +27.6% |
| 1 month ago | $9.59 | $1,177.27 | +17.7% |
| 3 months ago | $11.15 | $1,012.56 | +1.3% |
| 6 months ago | $10.03 | $1,125.62 | +12.6% |
| 1 year ago | $15.34 | $735.98 | -26.4% |
| All time (3.7y) ago | $7.14 | $1,582.15 | +58.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BHVN forecast.
Our base-case forecast reaches $23.00 around 2034.
Implied market cap at $23.00: $3.46B
The multi-year forecast shows an upside path with rising average prices and escalating upside potential. The 2026 forecast lists min $8.09, avg $11.29, max $16.63 with ROI 0 and neutral sentiment, followed by 2027 min $8.72, avg $11.61, max $16.62 with ROI 2.8 and neutral sentiment.
From 2028 onward, the outlook strengthens to a bullish stance: 2028 avg $14.83, 2029 avg $18.77, 2030 avg $19.25 (ROI 70.5), 2031 avg $20.45 (ROI 81.1), 2032 avg $18.55 (ROI 64.3), 2033 avg $19.22 (ROI 70.2), 2034 avg $25.00 (ROI 121.4), 2035 avg $26.98 (ROI 139), 2040 avg $34.51 (ROI 205.7), and 2050 avg $64.49 (ROI 471.2).
The 2050 max is $143.66 and the sentiment remains BULLISH across the longer horizon. These figures are estimates and not guarantees, and actual results can differ due to market and clinical outcomes."
Tap a question to reveal the answer.
2030 forecast: min $12.86, avg $19.25, max $31.21; ROI 70.5%; sentiment BULLISH.
Long-run forecasts show a bullish trajectory with rising averages and a max of $143.66 in 2050 (avg $64.49, ROI 471.2%). These are estimates, not guarantees.
Yes—the 2050 forecast lists a max of $143.66.
Current price $11.29 and market cap $1.7B.
30-day range is $8.55 to $14.91.
Biohaven Ltd. Community Discussion
0Share your Biohaven Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.